Comparison
Compare the outcomes before the reputations
A growth-hormone result, a cardiovascular event and a desire rating each answer a particular question. They resist a single league table.
Clinical outcomes across four compounds
Semaglutide leads my comparison because its studies cover a broader set of clinical outcomes. SELECT counted major cardiovascular events; FLOW counted major kidney-disease events. The former enrolled adults with existing cardiovascular disease and excess weight without diabetes; the latter enrolled people with type 2 diabetes and chronic kidney disease.
Tesamorelin's visceral and liver-fat trial concerned adults with HIV and abdominal fat accumulation. Bremelanotide's RECONNECT trials concerned desire and distress in premenopausal women with acquired, generalized HSDD. These are substantial clinical questions with narrower settings.
CJC-1295's healthy-adult work establishes prolonged growth-hormone and IGF-1 stimulation. A reader interested in sleep or strength arrives with an outcome those studies did not establish. Comparing that record with the other compounds helps locate the gap; it cannot fill it.
Aliases and altered forms
| Name encountered | Relationship | Consequence for comparison |
|---|---|---|
| PT-141 / bremelanotide | Names for the same active substance | Different papers may ask different questions about it. |
| Tesamorelin / TH9507 | Current and older research names | The HIV-associated fat results remain tied to their participants. |
| Semaglutide tablets / injections | Same active molecule, different formulations and routes | Each formulation needs its own clinical evidence. |
| CJC-1295 DAC / no-DAC | Albumin-binding addition present or absent | Duration differs; the long-acting findings cannot simply be assigned to Modified GRF. |
The albumin-conjugation experiment makes the last distinction concrete. Adding DAC changes a pharmacological property, whereas changing from the research name PT-141 to bremelanotide adds no new trial participants.